HYALOMATRIX
Anika Therapeutics, Inc. · Decision date Sep 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for HYALOMATRIX, a wound dressing submitted by Anika Therapeutics, Inc., under 510(k) number K261311, with a decision date of September 2, 2026 and product code QSZ. The public database lists the classification name as Absorbable Synthetic Wound Dressing and the review panel as General & Plastic Surgery. SESE means the device was cleared as substantially equivalent to a legally marketed predicate; it is not a premarket approval.
The 510(k) summary describes the submission as an update to the packaging configuration, together with changes to the finished device: dimensional specifications and removal of the silicone layer. The device is described as a sterile, single-use non-woven pad composed of HYAFF-11, a benzyl ester of hyaluronic acid. The summary names HYALOMATRIX under K073251, cleared December 14, 2007, as the predicate and states that no clinical study was required. The source does not resolve the discrepancy between the database receipt date of 04/21/2026 and the August 6, 2026 dates in the summary, and the specialty field is recorded as Unknown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Unknown
- Decision date
- Sep 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261311
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Anika Therapeutics, Inc.
- Product code
- QSZ
- Decision code
- SESE
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Absorbable Synthetic Wound Dressing.
- Applicant
- Anika Therapeutics, Inc.
- Product code
- QSZ
- FDA device class
- U
FDA decision timeline
K261311 received
Application receipt date recorded by FDA.
K261311 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QSZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RestrataK261245 | Acera Surgical, Inc. | 510(k) clearance | Oct 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Anika Therapeutics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Beford, MA
Sources and methodology
- Original FDA record: K261311
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records